Author Interviews, Biomarkers, Cancer Research, JAMA, University of Michigan / 21.04.2016
Biomarker Expression Linked to Aggressive Basal Cell Skin Cancer
MedicalResearch.com Interview with:
Alon Kahana, MD, PhD
Associate Professor
Kellogg Eye Center
University of Michigan
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Kahana: Basal cell carcinoma is the most common cancer - more common than all other cancers combined. Fortunately, it is usually not aggressive, and can be easily treated surgically. However, when it is on the face, or when it has grown to a large size, it can become very disfiguring and even deadly. Basal cell carcinoma is diagnosed histopathologically, yet molecular diagnostics have proven value in a variety of cancers. In order to improve diagnosis and care, we set out to test whether histologically aggressive forms of basal cell carcinoma are associated with increased cell proliferation.
Furthermore, we tested whether expression of the epigenetic regulator Ezh2 is associated with higher-grade carcinoma and/or with increased proliferation. The breakthrough discovery is that expression of Ezh2 correlates with high proliferation and with aggressive histologic features, suggesting that epigenetic regulators can be used both as markers of disease severity and targets of novel therapy. (more…)